Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment
S Boopathi, AB Poma, P Kolandaivel - Journal of Biomolecular …, 2021 - Taylor & Francis
In the past two decades, the world has faced several infectious disease outbreaks. Ebola,
Influenza A (H1N1), SARS, MERS, and Zika virus have had a massive global impact in terms …
Influenza A (H1N1), SARS, MERS, and Zika virus have had a massive global impact in terms …
The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19
Q Hu, Y Xiong, GH Zhu, YN Zhang, YW Zhang… - MedComm, 2022 - Wiley Online Library
The main proteases (Mpro), also termed 3‐chymotrypsin‐like proteases (3CLpro), are a
class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has …
class of highly conserved cysteine hydrolases in β‐coronaviruses. Increasing evidence has …
[HTML][HTML] Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
A new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), is the aetiological agent responsible for the 2019–2020 viral pneumonia outbreak of …
2), is the aetiological agent responsible for the 2019–2020 viral pneumonia outbreak of …
Potential SARS-CoV-2 main protease inhibitors
R Banerjee, L Perera, LMV Tillekeratne - Drug Discovery Today, 2021 - Elsevier
Highlights•The SARS-CoV-2 main protease is a prime drug target.•Coronavirus main
proteases share a structurally conserved substrate-binding region.•The structure and …
proteases share a structurally conserved substrate-binding region.•The structure and …
Recent progress in the drug development targeting SARS-CoV-2 main protease as treatment for COVID-19
W Cui, K Yang, H Yang - Frontiers in molecular biosciences, 2020 - frontiersin.org
The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2)
rapidly turned into an unprecedented pandemic of coronavirus disease 2019 (COVID-19) …
rapidly turned into an unprecedented pandemic of coronavirus disease 2019 (COVID-19) …
Anti-viral triterpenes: a review
P Darshani, S Sen Sarma, AK Srivastava… - Phytochemistry …, 2022 - Springer
Triterpenes are naturally occurring derivatives biosynthesized following the isoprene rule of
Ruzicka. The triterpenes have been reported to possess a wide range of therapeutic …
Ruzicka. The triterpenes have been reported to possess a wide range of therapeutic …
What coronavirus 3C‐like protease tells us: from structure, substrate selectivity, to inhibitor design
M Xiong, H Su, W Zhao, H Xie… - Medicinal research …, 2021 - Wiley Online Library
The emergence of a variety of coronaviruses (CoVs) in the last decades has posed huge
threats to human health. Especially, the ongoing pandemic of coronavirus disease 2019 …
threats to human health. Especially, the ongoing pandemic of coronavirus disease 2019 …
Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (Mpro) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular …
The novel SARS-CoV-2 is the etiological agent causing the Coronavirus disease 2019
(COVID-19), which continues to become an inevitable pandemic outbreak. Over a short …
(COVID-19), which continues to become an inevitable pandemic outbreak. Over a short …
Xanthohumol is a potent pan-inhibitor of coronaviruses targeting main protease
Coronaviruses cause diseases in humans and livestock. The SARS-CoV-2 is infecting
millions of human beings, with high morbidity and mortality worldwide. The main protease …
millions of human beings, with high morbidity and mortality worldwide. The main protease …
Review on development of potential inhibitors of SARS-CoV-2 main protease (MPro)
SG Katre, AJ Asnani, K Pratyush, NG Sakharkar… - Future Journal of …, 2022 - Springer
Background The etiological agent for the coronavirus illness outbreak in 2019–2020 is a
novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV …
novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV …